Abnormal synthesis of IgA in coeliac disease and related disorders

Journal of Biological Regulators and Homeostatic Agents

Volumn 22, Issue 2, 2008, Pages 99-104

  Cianci, R ^a   Cammarota, G ^a   Lolli, S ^a   Gasbarrini, G B ^a   Pandolfi, Franco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anti endomysial antibodies; Coeliac disease; HS1,2 enhancer; IgA; Tissue transglutaminase

Indexed keywords

BIOLOGICAL MARKER; ENDOMYSIUM ANTIBODY; GLIADIN ANTIBODY; HS 1 2 IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INTERFERON; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE TYPE 2 ANTIBODY;

ALLELE; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELIAC DISEASE; CELL DAMAGE; CELLULAR IMMUNITY; DERMATITIS HERPETIFORMIS; DISEASE MARKER; EDITORIAL; GENE FREQUENCY; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; SERODIAGNOSIS;

AUTOANTIBODIES; CELIAC DISEASE; ENHANCER ELEMENTS (GENETICS); HUMANS; IMMUNOGLOBULIN A; T-LYMPHOCYTES;

EID: 48749113478     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (36)

1. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002; 2: 647-55.
2. Cammarota G, Cuoco L, Cianci R, Pandolfi F, Gasbarrini G. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet 2000; 356:1494-5.
3. Hue S, Mention JJ, Monteiro RC et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004; 21:367-77.
4. Natter S, Granditsch G, Reichel GL et al. Ig cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease. Eur J Immunol 2001; 31:918-28.
5. Rostom A, Dube C, Cranney A et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology 2005; 128:S38-46.
6. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathology 2006; 208:270-82.
7. Sollid LM. Molecular basis of celiac disease. Ann Rev Immunol 2000; 18:53-81.
8. Schrodl D, Kahlenberg F, Peter-Zimmer K, Hermann W, Kuhn HJ, Mothes T. Intrathecal synthesis of autoantibodies against tissue transglutaminase. J Autoimmunity 2004; 22:335-40.
9. Hadjivassiliou M, Williamson CA, Woodroofe N. The immunology of gluten sensitivity: beyond the gut. Trends in Immunol 2004; 25:578-82.
10. Germenis AE, Yiannaki EE, ZachouK et al. Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. Clin Diagn Lab Immunol 2005; 12:941-8.
11. Sollid LM, Jabri B. Is celiac disease an autoimmune disorder? Curr Opin Immunol 2005; 17:595-600.
12. Bettendorf M, Doerr HG, Hauffa BP et al. Prevalence of autoantibodies associated with thyroid and celiac disease in Ullrich-Turner syndrome in relation to adult height after growth hormone treatment. J Pediatr Endocrinol Metabol 2006; 19:149-54.
13. Carroccio A, Iannitto E, Di Prima L et al. Screening for celiac disease in non-Hodgkin's lymphoma patients: a serum anti-transglutaminase-based approach. Dig Dis Sci 2003; 48:1530-6.
14. Peracchi M, Trovato C, Longhi M et al. Tissue transglutaminase antibodies in patients with end-stage heart failure. Am J Gastroenterol 2002; 97: 2850-4.
15. Farrace MG, Picarelli A, Di Tola M et al. Presence of anti-"tissue" transglutaminase antibodies in inflammatory intestinal diseases: an apoptosis-associated event? Cell Death Differ 2001; 8:767-70.
16. Kazemi-Shirazi L, Gasche CH, Natter S et al. IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases. Clin Exp Allergy 2002; 128:102-9.
17. Metzger MH, Heier M, Maki M et al. Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998. Eur J Epidemiol 2006; 21:359-65.
18. Dieterich W, Trapp D, Esslinger B et al. Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity. Gut 2003; 52:1562-6.
19. Kristjansson G, Venge P, Hallgren R. Mucosal reactivity to cow's milk protein in coeliac disease. Clin Exp Immunol 2007; 147:449-55.
20. Van der Boog PJ, Van Kooten C, De Fijter JW, Daha MR. Role of macromolecular IgA in IgA nephropathy. Kidney Int 2005; 67:813-21.
21. Helin H, Mustonen J, Reunala T, Pastemack A. IgA nephropathy associated with celiac disease and dermatitis herpetiformis. Arch Pathol Lab Med 1983; 107:324-7.
22. Almroth G, Axelsson T, Mussener E, Grodzinsky E, Midhagen G, Olcen P. Increased prevalence of anti-gliadin IgA-antibodies with aberrant duodenal histopathological findings in patients with IgA-nephropathy and related disorders. Ups J Med Sci 2006; 111:339-52.
23. Witte T, Matthias T, Arnett FC et al. IgA and IgG autoantibodies against alpha-fodrin as markers for Sjogren's syndrome. Systemic lupus erythematosus. J Rheumatol 2000; 27:2617-20.
24. Berglin E, Johansson T, Sundin U et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006; 65:453-8.
25. Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195:747-57.
26. Dieterich W, Laag E, Bruckner-Tuderman L et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999; 113:133-6.
27. Woo WK, McMillan SA, Watson RG, McCluggage WG, Sloan JM, McMillan JC. Coeliac disease-associated antibodies correlate with psoriasis activity. Br J Dermatol 2004; 151:891-4.
28. Riente L, Chimenti D, Pratesi F et al. Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol 2004; 31:920-4.
29. Hu Y, Pan Q, Pardali E et al. Regulation of germline promoters by the two human Ig heavy chain 3' alpha enhancers. J Immunol 2000; 164:6380-6.
30. Giambra V, Martinez-Labarga C, Giufre M et al. Immunoglobulin enhancer HS 1,2 polymorphism: a new powerful anthropogenetic marker. Ann Human Genet 2006; 70:946-50.
31. Denizot Y, Pinaud E, Aupetit C et al. Polymorphism of the human alphal immunoglobulin gene 3' enhancer hsl, 2 and its relation to gene expression. Immunology 2001; 103:35-40.
32. Aupetit C, Drouet M; Pinaud E et al. Alleles of the alpha1 immunoglobulin gene 3' enhancer control evolution of IgA nephropathy toward renal failure. Kidney Int 2000; 58:966-71.
33. Frezza D, Giambra V, Cianci R et al. Increased frequency of the immunoglobulin enhancer HS1,2 allele 2 in coeliac disease. Scand J Gastroenterol 2004; 39:1083-7.
34. Cianci R, Giambra V, Mattioli C et al. Increased Frequency of Ig Heavy-Chain HS1,2-A Enhancer (*)2 Allele in Dermatitis Herpetiformis, Plaque Psoriasis, and Psoriatic Arthritis. J Invest Dermatol 2008; doi: 10.1038/jid.2008.40.
35. Bentley DR. Genomes for medicine. Nature 2004; 429:440-5.
36. Hunt KA, Zhernakova A, Turner G et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Gen 2008; 40: 395-402.